Document Detail


Survival in subpopulations of cells derived from solid KHT sarcomas by centrifugal elutriation following treatment with CCNU and MISO.
MedLine Citation:
PMID:  6480449     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Misonidazole (MISO) has been shown to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in a number of different animal tumor systems. We have investigated the response to therapy of the various subpopulations of cells comprising the KHT sarcoma, to determine whether chemopotentiation occurred as a preferential enhancement of killing in one subpopulation of cells. Twenty-four hr after drug treatment, cells dissociated from solid tumors were separated into homogeneous populations based on cell size by the technique of centrifugal elutriation. By this method the majority of the non-neoplastic cells could be removed and the tumor cells separated into fractions containing 90 to 95% G1 cells, 70 to 75% S cells and 70 to 80% G2M cells. Clonogenic cell survival was measured for each elutriated fraction. In vivo treatment with 0.5 mg/g MISO produced no measurable cell-kill across the cell cycle. Those cells in late G1 and S phase 24 hr after treatment were most sensitive to CCNU alone. The enhancement of CCNU cytotoxicity by MISO occurred primarily in the early G1 and S fractions. These data suggest that chemopotentiation does not occur equally in all tumor cell subpopulations and that some specificity of enhanced cell killing exists.
Authors:
S A Hill; P C Keng; D W Siemann
Related Documents :
12239589 - Efficacy of chemopreventive agents for growth inhibition of apc [+/-] 1638ncol colonic ...
8567749 - Effect of cell cycle on the regulation of the cell surface and secreted forms of type i...
9112229 - Characterization of a cell cycle-dependent nuclear autoantigen.
2634429 - Cytotoxicity by tumor necrosis factor is linked with the cell cycle but does not requir...
9806609 - Radiation and the g2 phase of the cell cycle.
9889049 - Antisense blockade of p21/waf1 decreases radiation-induced g2 arrest in esophageal squa...
19733679 - Host cell death machinery as a target for bacterial pathogens.
22348829 - The anti-egfr antibody cetuximab sensitizes human head and neck squamous cell carcinoma...
18684719 - Hierarchical organization of lung progenitor cells: is there an adult lung tissue stem ...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  10     ISSN:  0360-3016     ISO Abbreviation:  Int. J. Radiat. Oncol. Biol. Phys.     Publication Date:  1984 Sep 
Date Detail:
Created Date:  1984-11-16     Completed Date:  1984-11-16     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1615-8     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cell Cycle
Cell Separation
Cell Survival / drug effects
Drug Synergism
Drug Therapy, Combination
Flow Cytometry
Lomustine / therapeutic use*
Mice
Mice, Inbred C3H
Misonidazole / therapeutic use*
Neoplasm Transplantation
Nitroimidazoles / therapeutic use*
Radiation-Sensitizing Agents / therapeutic use
Sarcoma, Experimental / drug therapy*
Grant Support
ID/Acronym/Agency:
CA-11051/CA/NCI NIH HHS; CA-11198/CA/NCI NIH HHS; CA-20329/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Nitroimidazoles; 0/Radiation-Sensitizing Agents; 13010-47-4/Lomustine; 13551-87-6/Misonidazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanism of melphalan crosslink enhancement by misonidazole pretreatment.
Next Document:  The effect in the KHT sarcoma of CCNU and MISO on cell cycle progression evaluated by flow-cytometry...